Key result
Pharmacological induction of TGF-beta1 with xaliproden significantly enhanced radiation-induced structural changes in the intestine and augmented radiation-induced changes in cardiac function and myocardial fibrosis.
Why the study?
Does pharmacological induction of TGF-beta1 with xaliproden enhance radiation injury in the intestine and heart in rat models?
Does pharmacological induction of TGF-beta1 with xaliproden enhance radiation injury in the intestine and heart in rat models?
Pharmacological induction of TGF-beta1 exacerbates radiation-induced structural and functional injury in the heart and intestine in rat models, supporting its mechanistic role in radiation toxicity.
Answers are grounded in this paper and cite their sources.
Xaliproden-augmented TGF-β1 worsens radiation heart and gut injury in rats; leaves open whether pathway inhibition mitigates toxicity in patients.
Radiation therapy in the treatment of cancer is dose limited by radiation injury in normal tissues such as the intestine and the heart. To identify the mechanistic involvement of transforming growth factor-beta 1 (TGF-β1) in intestinal and cardiac radiation injury, we studied the influence of pharmacological induction of TGF-β1 with xaliproden (SR 57746A) in rat models of radiation enteropathy and radiation-induced heart disease (RIHD). Because it was uncertain to what extent TGF-β induction may enhance radiation injury in heart and intestine, animals were exposed to irradiation schedules that cause mild to moderate (acute) radiation injury. In the radiation enteropathy model, male Sprague-Dawley rats received local irradiation of a 4-cm loop of rat ileum with 7 once-daily fractions of 5.6 Gy, and intestinal injury was assessed at 2 weeks and 12 weeks after irradiation. In the RIHD model, male Sprague-Dawley rats received local heart irradiation with a single dose of 18 Gy and were followed for 6 months after irradiation. Rats were treated orally with xaliproden starting 3 days before irradiation until the end of the experiments. Treatment with xaliproden increased circulating TGF-β1 levels by 300% and significantly induced expression of TGF-β1 and TGF-β1 target genes in the irradiated intestine and heart. Various radiation-induced structural changes in the intestine at 2 and 12 weeks were significantly enhanced with TGF-β1 induction. Similarly, in the RIHD model induction of TGF-β1 augmented radiation-induced changes in cardiac function and myocardial fibrosis. These results lend further support for the direct involvement of TGF-β1 in biological mechanisms of radiation-induced adverse remodeling in the intestine and the heart.
No takes yet. Share an insight, caveat, or question.
Boerma et al. (2013) studied Radiation enteropathy and radiation-induced heart disease (n=122). Xaliproden vs. Vehicle was evaluated on Radiation-induced structural changes in the intestine and heart (fibrosis, cardiac function) (p=<0.05). Pharmacological induction of TGF-beta1 with xaliproden significantly enhanced radiation-induced structural changes in the intestine and augmented radiation-induced changes in cardiac function and myocardial fibrosis.
Synapse has enriched 10 related papers. Consider them for comparative context: